*僅供醫學專業人士閱讀參考
中國研究者帶你直擊肺癌前沿
撰文丨張榕莘
萬眾期待的2024年歐洲肺癌大會(ELCC)將於當地時間3月20日-23日在捷克布拉格召開,作為肺癌領域備受關注的重要國際學術會議之一,ELCC匯聚了肺癌領域的全球專業大咖及其最新研究成果,形式多樣(包括口頭報告、壁報),其中,中國研究者不負眾望,展示前沿成果,向世界傳遞中國聲音!近日,ELCC官網線上公佈了摘要標題,醫學界小編特整理其精華內容,以飱讀者。
圍術期、晚期NSCLC治療領域多點開花
■108O
Surgical Outcomes from RATIONALE-315:Randomized,Double-Blind,Phase 3 Study of Perioperative Tislelizumab with Neoadjuvant Chemotherapy in Resectable NSCLC
隨機、雙盲、Ⅲ期RATIONALE-315研究的手術結果:替雷利珠單抗聯合新輔助化療圍手術期治療可切除(NSCLC)
講者:嶽東昇(天津醫科大學醫院)
■1MO
A Phase 3b Study of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation
賽沃替尼治療MET 14外顯子跳躍突變區域性晚期或轉移性NSCLC的一項IIIb期研究
講者:陸舜(附屬胸科醫院)
■61P
First-line camrelizumab(Camre)plus carboplatin(Carbo)and pemetrexed(Pem)for advanced non-squamous NSCLC:5-yr outcomes of CameL phase 3 study
卡瑞利珠單抗聯合卡鉑+培美曲塞治療晚期nsq-NSCLC的療效和安全性:Ⅲ期CameL研究的5年隨訪結果
講者:周彩存(同濟大學附屬上海市肺科醫院)
■62P
First-line(1L)camrelizumab plus chemotherapy(chemo)for advanced squamous non-small-cell lung cancer(sqNSCLC):4-yr update from the phase 3 CameL-sq trial
卡瑞利珠單抗聯合化療一線治療晚期鱗狀非小細胞肺癌(sqNSCLC):Ⅲ期CameL-sq研究的4年最新結果
講者:周彩存(同濟大學附屬上海市肺科醫院)
■68P
Phase 2 results of ivonescimab(ivo)a novel PD-1/VEGF bispecific in combination with chemotherapy for first line treatment of patients(pts)with advanced/metastatic squamous(Sq)non-small cell lung cancer(NSCLC)
新型PD-1/VEGF雙特異性抗體ivonescimab聯合化療一線治療晚期或轉移性sqNSCLC的Ⅱ期研究結果
講者:張力(中山大學腫瘤防治中心)
■70P
Phase II Clinical Study of Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as a First-Line Treatment for Driver Gene-Negative Advanced Non-Small Cell Lung Cancer
恩沃利單抗聯合重組人血管內皮抑制素和化療一線治療驅動基因陰性晚期NSCLC的Ⅱ期研究結果
講者:袁雙虎(山東第一醫科大學附屬腫瘤醫院)
■75P
PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center,phase 2 umbrella trial(CTONG 1702)
一項多中心、Ⅱ期傘式研究(CTONG 1702):PD-L1表達和腫瘤突變負荷指導信迪利單抗單藥一線治療晚期NSCLC
講者:劉思陽(暨南大學附屬第一醫院)
■102TiP
A Phase III randomised controlled trial of zongertinib(BI 1810631)compared with standard of care(SoC)in patients(pts)with locally advanced or metastatic non-squamous non-small cell lung cancer(NSCLC)harbouring HER2 tyrosine kinase domain(TKD)mutations:Beamion LUNG-2
比較zongertinib(BI 1810631)和標準治療(SoC)在HER2酪氨酸激酶域(TKD)突變陽性的區域性晚期或轉移性nsq-NSCLC患者中的應用
講者:吳一龍(廣東省人民醫院)
■174P
Intracranial(IC)Activity of Ivonescimab(ivo)Alone or In Combination with Platinum Doublet Chemotherapy(PC)in Patients(Pts)with Advanced Non-Small Cell Lung Cancer(aNSCLC)and Brain Metastases(BMs)
Ivonescimab±鉑類雙藥化療(PC)治療晚期NSCLC伴腦轉移患者的顱內活性
講者:張力(中山大學腫瘤防治中心)
SCLC廣泛期和侷限期全覆蓋!
■194MO
Phase II study of low-dose radiation(LDRT)plus durvalumab(D)and etoposide/platinum(EP)as first-line treatment in ES-SCLC(LEAD):efficacy and safety results
低劑量放療(LDRT)聯合度伐利尤單抗(D)和依託泊苷+順鉑(EP)一線治療廣泛期小細胞肺癌(ES-SCLC)的療效和安全性:一項Ⅱ期研究
講者:張衍(四川大學華西醫院)
■196MO
Anlotinib plus Etoposide/Carboplatin(EC)versus Placebo plus EC in First-line Therapy for Extensive-stage Small Cell Lung Cancer(ES-SCLC):A Randomized,Double-blind,Parallel controlled,Phase III Trial(ETER 701)
隨機、雙盲、平行對照的III期ETER 701研究:安羅替尼/安慰劑聯合依託泊苷+卡鉑(EC)一線治療ES-SCLC的療效和安全性
講者:程穎(吉林省腫瘤醫院)
■198P
Adebrelimab with concurrent chemoradiation(cCRT)for limited-stage small-cell lung cancer(LS-SCLC):safety run-in results of a phase 3 trial
阿得貝利單抗聯合同步放化療治療侷限期小細胞肺癌(LS-SCLC):一項Ⅲ期研究的安全性匯入期結果
講者:程穎(吉林省腫瘤醫院)
■216TiP
A phase II study of consolidation Serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer(ASTRUM-LC01)
Ⅱ期ASTRUM-LC01研究:低分割放療聯合化療後斯魯利單抗治療在LS-SCLC患者的應用
講者:Yuqi Wu(中國醫學科學院北京協和醫學院)
多方案助力精準治療EGFR突變肺癌
■137MO
Phase Ⅱ study of Becotarug(JMT101)Combined With Osimertinib in Patients(pts)With Locally Advanced or Metastatic NSCLC Harboring EGFR Exon 20 Insertion(ex20ins)Mutations(BECOME study)
Ⅱ期BECOME研究:Becotarug(JMT101)聯合奧希替尼治療EGFR 20外顯子插入(ex20ins)突變的區域性晚期或轉移性NSCLC患者
講者:張力(中山大學腫瘤防治中心)
■13P
Tislelizumab(TIS)plus chemotherapy(chemo)with or without bevacizumab(beva)for patients with EGFR-mutated nonsquamous non-small cell lung cancer(nsq-NSCLC)after progression on EGFR tyrosine kinase inhibitor(TKI)therapy
替雷利珠單抗聯合化療±貝伐珠單抗治療經EGFR-TKI治療後進展的、EGFR突變、非鱗狀非小細胞肺癌(nsq-NSCLC)
講者:韓寶惠(上海交通大學附屬胸科醫院)
■15P
Furmonertinib Combined with Anlotinib as the First-line Treatment in Patients with EGFR exon 21 Leu858Arg mutation:Results from FOCUS-A study
FOCUS-A研究結果:伏美替尼聯合安羅替尼一線治療EGFR 21號外顯子L858R突變患者的療效和安全性
講者:韓寶惠(上海交通大學附屬胸科醫院)
■17P
Efficacy and safety of Furmonertinib as salvage treatment for EGFR mutated NSCLC patients progressed on third-generation EGFR TKIs
伏美替尼治療經第3代EGFR-TKI治療後進展的EGFR突變NSCLC的療效和安全性
講者:侯雪(中山大學腫瘤防治中心)
■19P
Resistance Mechanism to First-Line Osimertinib in EGFR-Mutated(EGFRm)Advanced NSCLC(aNSCLC)in China:Preliminary data from FLOURISH study
FLOURISH研究的初步資料:奧希替尼一線治療EGFR突變的晚期NSCLC中國患者的耐藥機制
講者:周建婭(浙江大學醫學院附屬第一醫院)
■20P
Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure:An interim analysis of GPS study
GPS研究的中期分析:奧希替尼一線治療失敗後的EGFR突變的區域性晚期或轉移性 NSCLC 患者的基因組圖譜
講者:石遠凱(中國醫學科學院腫瘤醫院)
■98TiP
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
阿美替尼聯合安羅替尼一線治療EGFR/TP53共突變的晚期肺癌患者的療效和安全性
講者:姜戰勝(天津醫科大學腫瘤醫院)
■101TiP
The Efficacy and Safety of Furmonertinib in Advanced NSCLC Patients with EGFR Mutations and CNS Metastases Based on ctDNA Detection in Peripheral Blood and CSF(FAITH)
基於外周血和腦脊液ctDNA檢測,伏美替尼治療EGFR突變伴中樞神經系統轉移的NSCLC患者的療效和安全性
講者:李曉燕(首都醫科大學附屬北京天壇醫院)
■126P
Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-ⅢA Non-Small-Cell Lung Cancer:Updated Results From A multiple-center real-world experience
阿美替尼作為手術切除的EGFR突變NSCLC患者的輔助治療:一項多中心真實世界研究的最新結果
講者:Qingyi Zhang(浙江大學第一附屬醫院)
■143P
Efficacy and Safety of Aumolertinib(AUM)With Radiotherapy Versus Concurrent Chemoradiotherapy(cCRT)in the Treatment of Unresectable Stage III EGFR-mutant NSCLC:A Multicenter,Randomized,Open-Label Phase III Study(ADVANCE)
阿美替尼聯合放療或同步放化療治療不可切除的Ⅲ期EGFR突變NSCLC的療效和安全性:一項多中心、隨機、開放標籤III期研究(ADVANCE)
講者:畢楠(中國醫學科學院腫瘤醫院)
精彩資訊等你來
責任編輯:Sheep
*醫學界力求其發表內容專業、可靠,但不對內容的準確性做出承諾;請相關各方在採用或以此作為決策依據時另行核查。